Transtuzumab (Herceptin)

CAS NO: 180288-69-1
Batch Molecular FormulaC6470H10012N1726O2013S42
Batch Molecular Weight145531.5 g/mol
Physical AppearanceWhite to Pale yellow Solid powder
Solubility150mg Powder for Concentrate Solution
StorageStore at RT
Batch Molecular Structure

Trastuzumab, marketed under the brand name Herceptin, is a medication used in the treatment of certain types of cancer, primarily breast cancer. It is a monoclonal antibody that targets a specific protein called human epidermal growth factor receptor 2 (HER2). HER2 is a protein that promotes the growth of cancer cells, and in some cases, its overexpression is associated with aggressive forms of breast cancer.

Trastuzumab is primarily used for the following purposes:

  1. HER2-Positive Breast Cancer: Trastuzumab is a key component of the treatment for HER2-positive breast cancer. It is often used in combination with chemotherapy to treat both early-stage and metastatic (advanced) HER2-positive breast cancer. Trastuzumab helps slow down or stop the growth of cancer cells by targeting the HER2 protein.
  2. Stomach (Gastric) Cancer: In some cases, trastuzumab is used in the treatment of advanced stomach cancer (gastric or gastroesophageal junction adenocarcinoma) when the cancer cells overexpress the HER2 protein.

It’s important to note that trastuzumab is typically prescribed by oncologists and administered under their supervision. The treatment regimen, dosage, and duration can vary depending on the specific type and stage of cancer, as well as individual patient factors. Trastuzumab has shown significant benefits in improving the outcomes for individuals with HER2-positive breast cancer and certain types of stomach cancer. However, like all medications, it can have side effects, and its use should be carefully monitored by healthcare professionals.


  • Trastuzumab is used alone or with other medications to treat certain types of breast cancer.
  • It is also used along with other medications to treat certain types of stomach cancer.